8-K/A
filed November 21, 2022, 6:59 PM ET
ticker BVS
CIK 0001665988
earnings
confidence high
sentiment negative
materiality 0.85
Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance
Bioventus Inc.
2022-Q3 EPS reported
-$2.07
revenue$386,283,000
- Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.
- Net sales of $128.7M, +18.2% YoY; organic sales down 0.5%.
- FY2022 guidance cut: net sales now $517-522M (prev $547.5-562.5M); Adj. EBITDA $75-79M (prev $94-104M).
- Non-GAAP EPS guidance lowered to $0.20-0.25 from $0.47-0.57.
- Company discontinued development of MOTYS drug candidate.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Bioventus Inc. reported financial results for the nine months ended October 1, 2022.
- Period
- the nine months ended October 1, 2022
- Result
- reported results
Exact text from the filing
amended its previously announced financial results for the three and nine months ended October 1, 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Bioventus Inc. reported the three months ended October 1, 2022 results: revenue $128.7 million, net income $145.7 million, EPS $1.76.
- Period
- the three months ended October 1, 2022
- Revenue
- $128.7 million
- Net income
- $145.7 million
- EPS
- $1.76
- Result
- reported results
Exact text from the filing
• Net Sales of $128.7 million, up $19.8 million, or 18.2%, year-over-year as reported (19.1% constant currency*) and down (0.5%) organically* (0.3% constant currency*) • Net Loss of $145.7 million, compared to Net Loss of $2.3 million in prior-year period • Adjusted EBITDA* of $21.0 million, compared to $21.3 million in prior-year period • Loss per share of Class A common stock of $1.76, compared to $0.03 in prior-year period • Non-GAAP earnings per share of Class A common stock* of $0.06, compared to $0.19 in prior-year period
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Bioventus Inc. reported the twelve months ending December 31, 2022 results: revenue $517 million to $522 million, EPS $0.20 to $0.25. Guidance lowered.
- Period
- the twelve months ending December 31, 2022
- Revenue
- $517 million to $522 million
- EPS
- $0.20 to $0.25
- Guidance
- lowered
- Result
- guidance update
Exact text from the filing
• Net sales of $517 million to $522 million, representing year-over-year growth of approximately 20% to 21%, representing an update to the prior guidance of $547.5 million to $562.5 million. • Adjusted EBITDA* of $75 million to $79 million, compared to $80.8 million for the year ended December 31, 2021, and representing an update from the prior guidance of $94 million to $104 million. • Non-GAAP EPS* of $0.20 to $0.25, compared to $0.75 for the year ended December 31, 2021, and representing an update from the prior guidance of $0.47 to $0.57.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.